ArticleDigestive diseases and sciences2013
Lubiprostone decreases mouse colonic inner mucus layer thickness and alters intestinal microbiota.
Article in Digestive diseases and sciences, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 53 citations in OpenAlex.
- Enrichment of the lung microbiome with gut bacteria in sepsis and the acute respiratory distress syndrome.Nature microbiology · 2016Trial
- Coordinated regulation of colonic fluid and mucus secretion.Frontiers in pharmacology · 2026Review
- Comparative Effectiveness of Lubiprostone and Stool Softeners on Risk of Kidney Outcomes in Patients with CKD.Clinical journal of the American Society of Nephrology : CJASN · 2025Article
- Naringenin attenuates slow-transit constipation by regulating the AMPK/mTOR/ULK1 signalling pathway:Frontiers in pharmacology · 2025Article
- Rab7-dependent regulation of goblet cell protein CLCA1 modulates gastrointestinal homeostasis.eLife · 2024Article
- The ClC-2 Chloride Channel Activator, Lubiprostone, Improves Intestinal Barrier Function in Biopsies from Crohn's Disease but Not Ulcerative Colitis Patients.Pharmaceutics · 2023Article
- Intelectin-1 binds and alters the localization of the mucus barrier-modifying bacterium Akkermansia muciniphila.The Journal of experimental medicine · 2023Article
- Fueling Gut Microbes: A Review of the Interaction between Diet, Exercise, and the Gut Microbiota in Athletes.Advances in nutrition (Bethesda, Md.) · 2021Review
- The Impact of Gut Microbiota on Post-Stroke Management.Frontiers in cellular and infection microbiology · 2021Article
- Recent Progress in the Diagnosis and Precise Nanocarrier-Mediated Therapy of Inflammatory Bowel Disease.Journal of inflammation research · 2021Review
- Inflammatory Bowel Disease: The Emergence of New Trends in Lifestyle and Nanomedicine as the Modern Tool for Pharmacotherapy.Nanomaterials (Basel, Switzerland) · 2020Review
- Proteome and microbiota analysis highlightFood science & nutrition · 2020Article
- Bacterial Dissemination to the Brain in Sepsis.American journal of respiratory and critical care medicine · 2018Article
- An insight into intestinal mucosal microbiota disruption after stroke.Scientific reports · 2018Article
- New therapeutic perspectives in irritable bowel syndrome: Targeting low-grade inflammation, immuno-neuroendocrine axis, motility, secretion and beyond.World journal of gastroenterology · 2017Review
- Endurance exercise and gut microbiota: A review.Journal of sport and health science · 2017Review
- Article
- Ex Vivo Intestinal Sacs to Assess Mucosal Permeability in Models of Gastrointestinal Disease.Journal of visualized experiments : JoVE · 2016Article
- New Options in Constipation Management.Current oncology reports · 2015Review
- Deficiency of Group VIA Phospholipase A2 (iPLA2β) Renders Susceptibility for Chemical-Induced Colitis.Digestive diseases and sciences · 2015Article
Corrections and comments
- Commented on by
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
backgroundLubiprostone has been used to treat constipation through its effects to stimulate Cl(-) secretion, resulting in water and electrolyte secretion.
aimPotential associated changes in intestinal mucus and the colonizing bacteria (microbiome) have not been studied. As mucus obstructions may play a role in cystic fibrosis, the hypothesis that lubiprostone alters intestinal mucus and the microbiome was investigated.
methodsIon transport studies were performed ex vivo. For mucus and microbiome studies, mice were gavaged daily with lubiprostone or vehicle. Mucin from intestinal sections was analyzed in Carnoy's fixed tissues stained with Alcian blue. Microbiome composition was analyzed by 16S rRNA gene-based sequencing.
resultsLubiprostone stimulated short circuit current in all mouse intestinal segments after both serosal and mucosal additions, albeit at lower concentrations in the latter. Current was Cl-dependent and blocked by mucosal diphenylcarboxylic acid, serosal bumetanide, and serosal Ba(++). The CFTR inhibitor CFTRinh172 had a marginal effect. Mucus near epithelial cells (inner layer mucus) was not present in the small intestine of any mice. Proximal colon inner mucus layer was thicker in ∆F/∆F compared with +/∆F and +/+ mice. Lubiprostone decreased inner mucus layer thickness in both proximal and distal colon of all mice. Furthermore, lubiprostone altered the intestinal microbiome by increasing abundance of Lactobacillus and Alistipes.
conclusionsLubiprostone activates non-CFTR Cl(-) secretion and alters the colonic inner mucus layer, which is associated with changes in the composition of the enteric microbiome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.